Koers Sunshine Biopharma, Inc. Other OTC
Aandelen
US8677811064
Farmaceutische producten
Omzet 2024 * | 44,4 mln. 41,53 mln. | Omzet 2025 * | 100 mln. 93,53 mln. | Marktkapitalisatie | 945K 884K |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 2 mln. 1,87 mln. | Nettowinst (verlies) 2025 * | 16 mln. 14,96 mln. | EV/omzet 2024 * | 0,02 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,01 x |
K/w-verhouding 2024 * |
0,32
x | K/w-verhouding 2025 * |
0,06
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,55% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Steve Slilaty
CEO | Chief Executive Officer | 71 | 15-10-09 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 15-10-09 |
Marc Beaudoin
COO | Chief Operating Officer | - | 25/01 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David Natan
BRD | Director/Board Member | 70 | 01-02-22 |
Steve Slilaty
CEO | Chief Executive Officer | 71 | 15-10-09 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 15-10-09 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |